Veracyte, Inc. VCYT
25.57 USD +1.34 (+5.53%)
Regular-session close
25.51 -0.06 -0.23%
After hours · Nov 18, 6:41 PM ET
24.17 Day range 25.65
21.91 52-week range 60.91
- YTD
- -39.26%
- 1 year
- -34.03%
News
prnewswire.com Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law…
seekingalpha.com Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply,…benzinga.com Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40 Stephens & Co. analyst Mason Carrico maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $55 to $40.
benzinga.com Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30 Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.
benzinga.com Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40 Freedom Capital Markets analyst Keith Hinton maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $66 to $40.
benzinga.com UBS Maintains Buy on Veracyte, Lowers Price Target to $35 UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings U.S. stocks tumbled: Nasdaq -4.5%, S&P 500 -3.3%, Dow -2.5%. Cardinal Health rose on strong results; AppLovin surged 32%, while Veracyte fell 55%.
benzinga.com Why Is Veracyte Stock Sinking Thursday? Veracyte (VCYT) stock tumbled 54% to a new 52-week low as weaker-than-expected Decipher Prostate test volumes overshadowed Q3 earnings beat.
benzinga.com Dow Surges 250 Points; US Weekly Jobless Claims Fall U.S. stocks mixed: Dow +0.47%, Nasdaq -1.35%, S&P 500 -0.55%. Jobless claims fell to 189,000; oil and gold rose.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.benzinga.com Leerink Partners Downgrades Veracyte to Market Perform, Lowers Price Target to $35 Leerink Partners analyst Puneet Souda downgrades Veracyte (NASDAQ:VCYT) from Outperform to Market Perform and lowers the price target from $55 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…benzinga.com Needham Maintains Buy on Veracyte, Lowers Price Target to $46 Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $69 to $46.
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Veracyte Q3 2026 Earnings Call Transcript Veracyte (NASDAQ:VCYT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Veracyte Narrows FY2026 Sales Guidance from $590.000M-$596.000M to $590.000M-$593.000M vs $593.894M Est Veracyte (NASDAQ:VCYT) narrows FY2026 sales outlook from $590.000 million-$596.000 million to $590.000 million-$593.000 million vs $593.894 million estimate.
benzinga.com Veracyte Q3 Adj. EPS $0.51 Beats $0.41 Estimate, Sales $151.754M Beat $147.439M Estimate Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.41 by 24.39 percent. This is unchanged from the same period last year. The…
